Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2025-522956-25-00
2025-522956-25-00RecruitingPhase 3

COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial

Odense University Hospital3 sites in 1 country80 target enrollmentStarted: December 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
80
Locations
3
Primary Endpoint
The primary endpoint is the evaluation of the total pain burden during the 16-week treatment period. This is quantified using the validated Comprehensive Pain Assessment Tool - Short Form (COMPAT-SF). The primary analysis will be based on the Area Under the Curve (AUC) for the total pain score from baseline to week 16, comparing the Celecoxib group with the placebo group.
Study OverviewEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The aim of this investigator-initiated, randomized, controlled trial in adult Danish patients suffering from chronic pancreatitis (CP) is to evaluate the effect of Celecoxib, an oral NSAID, compared with placebo during 16 weeks of treatment. The primary objective is to assess patient-reported pain and quality of life (QoL) measured by the Comprehensive Pain Assessment Tool Short Form for Chronic Pancreatitis (COMPAT-SF).

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age: Male or female individuals aged >= 18 years.
  • •Diagnosis: Confirmed diagnosis of Chronic Pancreatitis (CP) according to the HaPanEU guidelines, established >= 6 months prior to screening.
  • •Pain Status: Symptomatic CP with a mean pain intensity >= 4 and <= 9 on a Numeric Rating Scale (NRS, 0-10) during the last 6 months.
  • •Renal Function: Plasma creatinine within normal local laboratory reference range at the time of screening.
  • •Contraception: For females of childbearing potential: Willingness to use a highly effective method of contraception (failure rate < 1% per year) throughout the treatment period.
  • •Communication: Ability to understand, read, and speak Danish to ensure reliable completion of Patient Reported Outcomes (PROs).
  • •Compliance: The investigator assesses that the participant is capable of understanding the trial requirements and is expected to comply with all study procedures.
  • •Informed Consent: Ability to provide written informed consent prior to any study-related procedures.

Exclusion Criteria

  • •Recent Acute Pancreatitis: Diagnosed with acute pancreatitis requiring hospitalization within 4 weeks prior to screening.
  • •General Safety Exclusion: Any other clinical condition or laboratory abnormality that, in the opinion of the investigators, makes the patient unsuitable for participation.
  • •Prior NSAID Use: Use of any Non-Steroidal Anti-Inflammatory Drug (NSAID) within 30 days prior to screening.
  • •Prohibited Medication: Current use of ACE-inhibitors, Angiotensin-II-receptor blockers, Direct Oral Anticoagulants (DOACs), or Acetylsalicylic acid.
  • •Hypersensitivity: Known allergy or hypersensitivity to Celecoxib, sulfonamides, or other NSAIDs (including history of NSAID-induced asthma or urticaria).
  • •Gastrointestinal Disease: History of peptic ulcer, gastrointestinal hemorrhage, or active inflammatory bowel disease (IBD).
  • •Renal or Hepatic Impairment: History of known chronic renal insufficiency, hepatic cirrhosis, or severe hepatic impairment.
  • •Established Cardiovascular Disease: History of heart failure (NYHA II-IV), coronary artery disease, angina pectoris, myocardial infarction, stroke, or transient ischemic attack (TIA).
  • •Cardiovascular Risk (SCORE2): Moderate-to-high risk of cardiovascular disease assessed by SCORE2/SCORE2-OP tools exceeding: >5.0% (age 40-59), >7.5% (age 60-69), or >10% (age 70-75).
  • •Pregnancy and Lactation: Confirmed or suspected pregnancy, planning of pregnancy during the treatment period, or breastfeeding.

Arms & Interventions

Pantoprazole 40 mg gastro-resistant tablets

Auxiliary

Intervention: Pantoprazole 40 mg gastro-resistant tablets (Drug)

CELECOXIB

Test

Intervention: CELECOXIB (Drug)

Placebo matching celecoxib 200 mg hard capsules

Placebo

Intervention: Placebo matching celecoxib 200 mg hard capsules (Drug)

Outcomes

Primary Outcomes

The primary endpoint is the evaluation of the total pain burden during the 16-week treatment period. This is quantified using the validated Comprehensive Pain Assessment Tool - Short Form (COMPAT-SF). The primary analysis will be based on the Area Under the Curve (AUC) for the total pain score from baseline to week 16, comparing the Celecoxib group with the placebo group.

The primary endpoint is the evaluation of the total pain burden during the 16-week treatment period. This is quantified using the validated Comprehensive Pain Assessment Tool - Short Form (COMPAT-SF). The primary analysis will be based on the Area Under the Curve (AUC) for the total pain score from baseline to week 16, comparing the Celecoxib group with the placebo group.

Secondary Outcomes

  • Weekly Pain Profile: Change in pain intensity measured weekly throughout the 16-week treatment period using the Izbicki Pain Score.
  • Opioid Consumption: Change in total daily dose of opioids, calculated as Oral Morphine Equivalents (OME), from baseline to week 16.
  • Systemic Inflammation: Change in plasma levels of high-sensitivity C-reactive protein (hs-CRP) from baseline to week 16.
  • Overall Clinical Benefit: Proportion of patients reporting "adequate pain relief" (yes/no) at the end of the study.
  • Disease Activity: Incidence of hospital admissions related to Chronic Pancreatitis (CP) and acute pancreatitis (AP) flares, defined as amylase levels > 180 U/L in venous plasma
  • Health-Related Quality of Life: Change in Quality of Life (QoL) measured by the validated Short Form 36 (SF-36) questionnaire, completed at the same intervals as COMPAT-SF.
  • Safety and Tolerability: Incidence and severity of adverse events (AEs), with specific focus on peptic ulcer, gastrointestinal hemorrhage, impaired renal function, cardiovascular injury, hepatocellular injury, respiratory tract symptoms, and all-cause mortality.

Investigators

Sponsor Class
Hospital/Clinic/Other health care facility
Responsible Party
Principal Investigator
Principal Investigator

Ove B. Schaffalitzky de Muckadell

Scientific

Odense University Hospital

Study Sites (3)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)Cancer of Unknown Primary Site
NCT07366008Haukeland University Hospital350
Active, not recruiting
Not Applicable
Clinical Trial on the Efficacy and Safety of ALT001 in OsteoarthritisOsteoarthritis
NCT07404891Union Hospital, Tongji Medical College, Huazhong University of Science and Technology30
Not yet recruiting
Not Applicable
NEUROCUPLE™ as an Opioid Alternative Following Total Knee ArthroplastyTotal Knee Arthroplasty Postoperative PainOpioid Reduction After TKA
NCT07439666Jacques E. Chelly274
Not yet recruiting
Phase 3
Study the wound healing effect of ayurvedic medicine on wound of opening of uterusInflammatory disease of cervix uteri. Ayurveda Condition: VRANAH,
CTRI/2024/04/065462Dr Archana Subhash Jadhav156
Not yet recruiting
Phase 2
Comparison of two types of nerve blocks to reduce pain after renal surgeries.Other disorders of kidney and ureter in diseases classified elsewhere, (2) ICD-10 Condition: 8||Other Procedures,
CTRI/2025/09/095506School of medical sciences and research50